| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/40-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CS-1; CMH16; C4orf5 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MYOZ2抗体的3篇参考文献示例(注：文献为虚构示例，实际引用需核实原文)：
---
1. **文献名称**: *Myozenin-2 (MYOZ2) as a novel biomarker in hypertrophic cardiomyopathy*
**作者**: Tanaka K, et al.
**摘要**: 本研究通过开发兔源多克隆MYOZ2抗体，利用免疫组化和Western blot技术，首次在人类肥厚型心肌病(HCM)患者心肌样本中证实MYOZ2蛋白表达显著上调，提示其可能参与病理性心肌重塑的调控通路。
2. **文献名称**: *Characterization of MYOZ2 interaction with Z-disc proteins in skeletal muscle*
**作者**: Müller S, et al.
**摘要**: 文章利用小鼠单克隆MYOZ2抗体(克隆号：3A8)，通过免疫共沉淀和质谱分析，揭示了MYOZ2与α-actinin、Calsarcin-1等Z盘蛋白的相互作用网络，为骨骼肌收缩机制提供了分子层面的新见解。
3. **文献名称**: *Development of a high-affinity monoclonal antibody for MYOZ2 and its application in cardiac fibrosis models*
**作者**: Zhang Y, et al.
**摘要**: 该研究报道了一种高特异性抗人MYOZ2单克隆抗体的制备与验证，通过免疫荧光和流式细胞术，证明MYOZ2在心脏纤维化模型中的动态表达变化，支持其作为治疗靶点的潜力。
---
**提示**：实际研究中，建议通过PubMed或Web of Science以“MYOZ2 antibody”或“Myozenin-2 immunodetection”为关键词检索，并筛选涉及抗体开发、验证或应用的原创研究。商业抗体厂商(如Abcam、Santa Cruz)的技术手册也可提供部分应用参考文献。
The MYOZ2 antibody targets myozenin-2 (MYOZ2), a striated muscle-specific protein belonging to the myozenin family, which plays a critical role in anchoring and stabilizing Z-disc components in sarcomeres. MYOZ2. encoded by the *MYOZ2* gene on human chromosome 4q26. interacts with calcineurin, α-actinin, and γ-filamin, modulating signaling pathways involved in muscle development, hypertrophy, and stress response. It is predominantly expressed in cardiac and skeletal muscle, where it contributes to structural integrity and mechanotransduction. Dysregulation of MYOZ2 has been linked to cardiomyopathies, including hypertrophic cardiomyopathy (HCM), due to its influence on calcineurin/NFAT signaling, a pathway critical for cardiac remodeling.
Antibodies against MYOZ2 are widely used in research to investigate its expression, localization, and functional roles in muscle physiology and disease. They enable techniques like Western blotting, immunohistochemistry, and immunofluorescence to study MYOZ2’s interaction partners, post-translational modifications, and tissue-specific distribution. Commercial MYOZ2 antibodies are typically validated for specificity using knockout controls or siRNA-mediated knockdown. Recent studies also explore MYOZ2’s potential as a biomarker or therapeutic target in cardiac disorders. However, variability in antibody performance across species or experimental conditions requires careful validation to ensure reproducibility in research applications.
×
